曲妥珠单抗emtansine治疗HER2阳性非小细胞肺癌的II期研究
这项II期研究评估了T-DM1单药治疗HER2阳性复发NSCLC的疗效与安全性,因疗效有限提前终止。15例可评估患者中客观缓解率6.7%,中位无进展生存期2.0个月,中位生存期10.9个月,常见3-4级不良事件为血小板减少和肝毒性。
要点
- T-DM1在HER2阳性NSCLC中客观缓解率仅6.7%,疗效有限。
- 中位无进展生存期2.0个月,中位生存期10.9个月。
- 3-4级不良事件以血小板减少(40%)和肝毒性(20%)为主。
核心结论
- T-DM1单药在HER2阳性复发NSCLC中疗效有限,研究因疗效不足提前终止。
研究设计与样本
- II期临床试验,纳入HER2阳性(IHC 3+、IHC 2+且FISH阳性或外显子20突变)复发NSCLC患者,15例可评估。
主要发现
- 1例患者达到部分缓解,客观缓解率6.7%(90% CI: 0.2-32.0)。
- 中位随访9.2个月,中位无进展生存期2.0个月,中位生存期10.9个月。
- 3-4级不良事件包括血小板减少(40%)和肝毒性(20%),无治疗相关死亡。
关键数值与推荐
- HER2阳性定义:IHC 3+,或IHC 2+且FISH阳性,或外显子20突变。
- 患者特征:中位年龄67岁,男性47%,PS 0-1占80%,IHC 3+占33%,IHC 2+/FISH阳性占20%,外显子20突变占47%。
- 中位给药周期数为3(范围1-11)。
临床怎么用
- T-DM1单药不作为HER2阳性NSCLC的推荐治疗选择。
- 对于HER2阳性NSCLC,需探索其他分子靶向策略。
局限性
- 样本量小(15例可评估),研究提前终止。
- 单臂设计,无对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Trastuzumab emtansine (T-DM1), an anti-erb-b2 receptor tyrosine kinase 2 (HER2) antibody-drug conjugate, has been shown to significantly improve survival in HER2-positive breast cancer. We report a phase II trial of T-DM1 monotherapy in relapsed NSCLC with documented HER2 positivity (an immunohistochemistry [IHC] score of 3+, both an IHC score of 2+ and fluorescence in situ hybridization positivity, or exon 20 mutation). This study was terminated early because of limited efficacy. The demographic characteristics in the 15 assessable patients were as follows: median age, 67 years; male sex, 47%; performance status of 0 to 1, 80%; HER2 status IHC 3+, 33%; HER status IHC 2+/fluorescence in situ hybridization-positive, 20%; and exon 20 mutation, 47%. The median number of delivered cycles was 3 (range 1-11). One patient achieved a partial response with an objective response rate of 6.7% (90% confidence interval: 0.2-32.0). With a median follow-up time of 9.2 months, the median progression-free survival time and median survival time were 2.0 and 10.9 months, respectively. Grade 3 or 4 adverse events included thrombocytopenia (40%) and hepatotoxicity (20%) without any treatment-related deaths. T-DM1 had a limited efficacy for HER2-positive NSCLC in our cohort. Applying the concept of precision medicine to tumors appears challenging; thus, additional molecular approaches are warranted.
引用
- Hotta K, Aoe K, Kozuki T, et al. A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 29313813. doi:10.1016/j.jtho.2017.10.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。